Skip to content
Recall Observatory FDA recall evidence

Exact FDA event identifier

Event 93867

2 recalled-product records grouped only because every row carries this exact official event ID.

Open FDA event record

Event summary

Timeline bucket
January 25, 2024
Product types
Drug
Classifications
Class III
Statuses
Ongoing
Recalling firm wording
Teva Pharmaceuticals USA, Inc

Dossier provenance

Source snapshots represented here

  • openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Complete imported group

Every recalled product in this event

2 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 2

Nortrel (norethindrone and ethinyl estradiol tablets USP) 0.5/35, packaged in cartons, each carton contains 3 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9008-67

D-0321-2024
Recall number
D-0321-2024
Initiated
January 25, 2024
Classification
Class III
Status
Ongoing
Quantity
12,916 cartons

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Code information

Lot #: 100042978, Exp 7/31/2024

Distribution pattern

nationwide

drug · product 2 of 2

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58

D-0322-2024
Recall number
D-0322-2024
Initiated
January 25, 2024
Classification
Class III
Status
Ongoing
Quantity
19,824 cartons

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Code information

Lot #: 100040731, Exp 7/31/2024

Distribution pattern

nationwide